Clinical-stage biotechnology company Acepodia has raised $100m in a Series D financing round to advance the first-in-class cell therapies being developed using the antibody-cell conjugation (ACC) platform.
The financing round, led by Digital Mobile Venture, has also seen participation from other existing investors.
The latest funding brings the total venture capital financing secured by the company so far to $259m.
The company raised $109m in a Series C financing round completed in December 2021 and $47m in a Series B round in March 2021.
Acepodia will use the proceeds from the Series D round to advance its cell therapies pipeline, including ACE1831 and ACE2016, to treat solid tumours and haematologic cancers.
ACE1831 is an anti-CD20 armed allogeneic gamma delta 2 T-cell therapy now being evaluated in a Phase I trial in non-Hodgkin lymphoma patients.
ACE1931 is an off-the-shelf therapy targeting CD20-expressing haematological cancers.
ACE 2016 is an anti-EGFR armed allogeneic gamma delta 2 T-cell therapy that targets epidermal growth factor receptor (EGFR)-expressing solid tumours.
It has demonstrated promising cytotoxicity against a number of EGFR-expressing cancers in previous study models, using the company’s γδ2 T cell platform and the ACC technology.
Acepodia CEO Sonny Hsiao stated: “These funds will directly promote the progression of our clinical and pre-clinical candidates and also continue the validation of our ACC and allogeneic gamma delta 2 T-cell platforms to advance the development of innovative, effective and importantly affordable off-the-shelf allogeneic cell therapies.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
